Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02666950 · OUTCOME

Time to Response, Defined as the Time From Registration to the Earliest Date of Documentation of Response

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome · Source last updated 2019-09-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 17 months

What was measured

Time to response, defined as the time from registration to the earliest date of documentation of response. The distribution of time to progression will be estimated using the method of Kaplan-Meier.

Analysis population: No patients responded, thus no patients were analyzed for this outcome measure. Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.

Groups in this outcome

Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)

Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Time to response, defined as the time from registration to the earliest date of documentation of response. The distribution of time to progression will be estimated using the method of Kaplan-Meier.
groups
  1. description
    Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.
    id
    OG000
    title
    Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)
population Description
No patients responded, thus no patients were analyzed for this outcome measure. Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.
reporting Status
POSTED
time Frame
Up to 17 months
title
Time to Response, Defined as the Time From Registration to the Earliest Date of Documentation of Response
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice